Human Papillomavirus Testing in Cervical Cancer Screening

Philip E. Castle; Miriam Cremer

doi:10.1016/j.ogc.2013.03.002

Human Papillomavirus Testing in Cervical Cancer Screening

Philip E. Castle, Miriam Cremer

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

Human papillomavirus (HPV) testing is more reliable and sensitive but less specific than Papanicolaou (Pap) testing/cervical cytology for the detection of cervical precancer and cancer. HPV-negative women are at lower risk of cervical cancer than Pap-negative women. In high-resource settings, HPV testing can be used to make cervical cancer prevention programs more efficient by focusing clinical attention on women who have HPV. In lower-resource settings, where Pap testing has not been sustained or widespread, new, lower-cost HPV tests may make cervical cancer screening feasible.

Original language	English (US)
Pages (from-to)	377-390
Number of pages	14
Journal	Obstetrics and Gynecology Clinics of North America
Volume	40
Issue number	2
DOIs	https://doi.org/10.1016/j.ogc.2013.03.002
State	Published - Jun 2013
Externally published	Yes

Keywords

Cervical cancer
Cervical intraepithelial neoplasia
Human papillomavirus (HPV)
Low-resource settings
Pap testing
Screening
Vaccination
Visual inspection after acetic acid (VIA)

ASJC Scopus subject areas

Obstetrics and Gynecology

Access to Document

10.1016/j.ogc.2013.03.002

Fingerprint Dive into the research topics of 'Human Papillomavirus Testing in Cervical Cancer Screening'. Together they form a unique fingerprint.

Cite this

@article{a521ce277f664f328943681b7c3cea01,

title = "Human Papillomavirus Testing in Cervical Cancer Screening",

abstract = "Human papillomavirus (HPV) testing is more reliable and sensitive but less specific than Papanicolaou (Pap) testing/cervical cytology for the detection of cervical precancer and cancer. HPV-negative women are at lower risk of cervical cancer than Pap-negative women. In high-resource settings, HPV testing can be used to make cervical cancer prevention programs more efficient by focusing clinical attention on women who have HPV. In lower-resource settings, where Pap testing has not been sustained or widespread, new, lower-cost HPV tests may make cervical cancer screening feasible.",

keywords = "Cervical cancer, Cervical intraepithelial neoplasia, Human papillomavirus (HPV), Low-resource settings, Pap testing, Screening, Vaccination, Visual inspection after acetic acid (VIA)",

author = "Castle, {Philip E.} and Miriam Cremer",

year = "2013",

month = jun,

doi = "10.1016/j.ogc.2013.03.002",

language = "English (US)",

volume = "40",

pages = "377--390",

journal = "Obstetrics and Gynecology Clinics of North America",

issn = "0889-8545",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Human Papillomavirus Testing in Cervical Cancer Screening

AU - Castle, Philip E.

AU - Cremer, Miriam

PY - 2013/6

Y1 - 2013/6

N2 - Human papillomavirus (HPV) testing is more reliable and sensitive but less specific than Papanicolaou (Pap) testing/cervical cytology for the detection of cervical precancer and cancer. HPV-negative women are at lower risk of cervical cancer than Pap-negative women. In high-resource settings, HPV testing can be used to make cervical cancer prevention programs more efficient by focusing clinical attention on women who have HPV. In lower-resource settings, where Pap testing has not been sustained or widespread, new, lower-cost HPV tests may make cervical cancer screening feasible.

AB - Human papillomavirus (HPV) testing is more reliable and sensitive but less specific than Papanicolaou (Pap) testing/cervical cytology for the detection of cervical precancer and cancer. HPV-negative women are at lower risk of cervical cancer than Pap-negative women. In high-resource settings, HPV testing can be used to make cervical cancer prevention programs more efficient by focusing clinical attention on women who have HPV. In lower-resource settings, where Pap testing has not been sustained or widespread, new, lower-cost HPV tests may make cervical cancer screening feasible.

KW - Cervical cancer

KW - Cervical intraepithelial neoplasia

KW - Human papillomavirus (HPV)

KW - Low-resource settings

KW - Pap testing

KW - Screening

KW - Vaccination

KW - Visual inspection after acetic acid (VIA)

UR - http://www.scopus.com/inward/record.url?scp=84878625615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878625615&partnerID=8YFLogxK

U2 - 10.1016/j.ogc.2013.03.002

DO - 10.1016/j.ogc.2013.03.002

M3 - Review article

C2 - 23732037

AN - SCOPUS:84878625615

VL - 40

SP - 377

EP - 390

JO - Obstetrics and Gynecology Clinics of North America

JF - Obstetrics and Gynecology Clinics of North America

SN - 0889-8545

IS - 2

ER -

Human Papillomavirus Testing in Cervical Cancer Screening

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this